{
    "clinical_study": {
        "@rank": "149742", 
        "arm_group": [
            {
                "arm_group_label": "Dose Escalation Cohorts", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose Expansion Cohort with bevacizumab [Avastin]", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose Expansion Cohort without bevacizumab [Avastin]", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, multicenter, phase 1b study will evaluate the safety and pharma cokinetics\n      of DNIB0600A in patients with platinum-sensitive ovarian cancer. The maximum tolerated dose\n      of intravenously infused DNIB0600A in combination with ca rboplatin will be determined in\n      escalating dose cohorts. The combination of DNIB 0600A and carboplatin will then be\n      evaluated with and without bevacizumab [Avast in] in two dose expansion cohorts."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >/= 18 years.\n\n          -  Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.\n\n          -  Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or\n             fallopian tube cancer that is platinum sensitive.\n\n          -  Platinum-sensitive ovarian cancer with documented radiographic progression or relapse\n             within 6 to 18 months of most recent platinum-based chemotherapy.\n\n          -  Available tumor specimen.\n\n          -  Measurable disease.\n\n          -  Female patients of childbearing potential must use effective contraception as defined\n             by study protocol and cannot be pregnant or breastfeeding.\n\n        Exclusion Criteria:\n\n          -  Anti-tumor therapy of any kind or major surgery within 4 weeks prior to Day 1.\n\n          -  Platinum-based chemotherapy within 6 months prior to Day 1.\n\n          -  Palliative radiation within 2 weeks prior to Day 1.\n\n          -  Toxicity (except alopecia and anorexia) from prior therapy or neuropathy of grades >\n             1.\n\n          -  Evidence of any significant disease or condition that could affect compliance with\n             the protocol or interpretation of results.\n\n          -  Known active infection (except fungal nail infections).\n\n          -  History of liver disease or HIV.\n\n          -  Other malignancy within the last 5 years, except for adequately treated or controlled\n             carcinoma in situ of the cervix or skin cancer or primary endometrial cancer of stage\n             </= 1B.\n\n          -  Untreated or active CNS metastases.\n\n          -  Prior treatment with NaPi2b- targeted therapy.\n\n        Bevacizumab [Avastin]-Specific Exclusion Criteria:\n\n          -  Inadequately controlled hypertension or history of hypertensive crisis or\n             encephalopathy.\n\n          -  History of heart problems or thrombosis within 6 months prior to study start.\n\n          -  History of stroke within 6 months prior to study enrollment.\n\n          -  History of significant vascular disease.\n\n          -  History of expectoration of blood within 1 month prior to study start or blood\n             clotting problems.\n\n          -  Core biopsy or other minor surgical procedure within 7 days prior to study start\n\n          -  Serious and non-healing wound, active ulcer, or untreated bone fracture."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995188", 
            "org_study_id": "GO29006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose Escalation Cohorts", 
                "description": "Escalating doses of intravenously administered DNIB0600A", 
                "intervention_name": "DNIB0600A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose Expansion Cohort with bevacizumab [Avastin]", 
                    "Dose Expansion Cohort without bevacizumab [Avastin]"
                ], 
                "description": "Intravenous administration of a fixed dose of DNIB0600A", 
                "intervention_name": "DNIB0600A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose Escalation Cohorts", 
                    "Dose Expansion Cohort with bevacizumab [Avastin]", 
                    "Dose Expansion Cohort without bevacizumab [Avastin]"
                ], 
                "description": "An IV infusion at a dose of AUC 6 mg/mL * min", 
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose Expansion Cohort with bevacizumab [Avastin]", 
                "description": "IV infusion at 15 mg/kg", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO29006 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose-limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Incidence of adverse events (AE)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 months"
            }, 
            {
                "measure": "Incidence of anti-DNIB0600A antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration-time curve (AUC) of DNIB0600A", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Objective response determined by Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "More than 4 weeks after baseline evaluation"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 months"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}